awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33846405-959B6B84-A2E8-4114-A733-68D9899B36D4
Q33846405-959B6B84-A2E8-4114-A733-68D9899B36D4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33846405-959B6B84-A2E8-4114-A733-68D9899B36D4
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
P2860
Q33846405-959B6B84-A2E8-4114-A733-68D9899B36D4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33846405-959B6B84-A2E8-4114-A733-68D9899B36D4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cc28292e0391aa7f231a53de515de4b7f566d712
P2860
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer